Compare · ABBV vs MLYS
ABBV vs MLYS
Side-by-side comparison of AbbVie Inc. (ABBV) and Mineralys Therapeutics Inc. (MLYS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and MLYS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $458.24B, about 208.0x MLYS ($2.20B).
- Over the past year, ABBV is up 37.6% and MLYS is up 96.4% - MLYS leads by 58.8 points.
- MLYS has been more active in the news (12 items in the past 4 weeks vs 5 for ABBV).
- ABBV has more recent analyst coverage (25 ratings vs 10 for MLYS).
- Company
- AbbVie Inc.
- Mineralys Therapeutics Inc.
- Price
- $259.26+0.91%
- $26.73-0.98%
- Market cap
- $458.24B
- $2.20B
- 1M return
- +10.36%
- +3.69%
- 1Y return
- +37.55%
- +96.40%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2023
- News (4w)
- 5
- 12
- Recent ratings
- 25
- 10
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Latest ABBV
- Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
- SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
- SEC Form 4 filed by Director Rapp Edward J
- SEC Form 4 filed by Director Quaggin Susan E
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- FDA Approval for SKYRIZI issued to ABBVIE INC
Latest MLYS
- Chief Commercial Officer Warren Eric exercised 7,438 shares at a strike of $13.24 and sold $199,885 worth of shares (7,438 units at $26.87) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Chief Medical Officer Rodman David Malcom sold $11,036 worth of shares (416 units at $26.53) as part of a pre-agreed trading plan and exercised 416 shares at a strike of $15.44 (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Chief Executive Officer Congleton Jon sold $291,441 worth of shares (10,700 units at $27.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 603,621 units (SEC Form 4)
- Chief Medical Officer Rodman David Malcom exercised 14,058 shares at a strike of $7.28 and sold $556,671 worth of shares (20,407 units at $27.28) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 51,384 units (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Amendment: SEC Form 144/A filed by Mineralys Therapeutics Inc.
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- SEC Form 144 filed by Mineralys Therapeutics Inc.